Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Collins

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
BMC Cancer|June 2, 2022
Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)Lucy Gately, Katharine Drummond, Mark Rosenthal, et al.
Bioorganic & Medicinal Chemistry|December 22, 2009
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2Stephen Hilton, Sebastien Naud, John J Caldwell, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2012
An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacyNeil R Stokes, Nicola Baker, James M Bennett, et al.
Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.
Eclinicalmedicine|October 7, 2025
The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patientsNisha A George, Daniel Pan, Luisa Silva, et al.
The EMBO Journal|February 15, 2011
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein responseMaruf M U Ali, Tina Bagratuni, Emma L Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 16, 2013
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibitionYann Touchefeu, Aadil A Khan, Gerben Borst, et al.
Molecular Cancer Therapeutics|January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106Michael I Walton, Paul D Eve, Angela Hayes, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerasesNeil R Stokes, Helena B Thomaides-Brears, Stephanie Barker, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
BMC Cancer|June 2, 2022
Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)Lucy Gately, Katharine Drummond, Mark Rosenthal, et al.
Bioorganic & Medicinal Chemistry|December 22, 2009
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2Stephen Hilton, Sebastien Naud, John J Caldwell, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2012
An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacyNeil R Stokes, Nicola Baker, James M Bennett, et al.
Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.
Eclinicalmedicine|October 7, 2025
The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patientsNisha A George, Daniel Pan, Luisa Silva, et al.
The EMBO Journal|February 15, 2011
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein responseMaruf M U Ali, Tina Bagratuni, Emma L Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 16, 2013
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibitionYann Touchefeu, Aadil A Khan, Gerben Borst, et al.
Molecular Cancer Therapeutics|January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106Michael I Walton, Paul D Eve, Angela Hayes, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerasesNeil R Stokes, Helena B Thomaides-Brears, Stephanie Barker, et al.
Pageof 11